Reader-Supported · Editorially Reviewed
§ Side-By-Side · TRT & Men's Hormones

Hone Health vs Peter MD: TRT Platforms Compared

Hone Health and Peter MD are both TRT-first telehealth platforms, but they take different approaches: Hone leans heavily on biomarker testing and women's hormone support; Peter MD is a men-only program that bundles TRT with GLP-1-based weight loss.

2 studies cited
Fact-checked 12 May 2026Last updated 12 May 2026Independent Comparison

We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology

Hone Health and Peter MD are both men's health platforms with a strong TRT focus, but they approach the category differently. Hone Health is a TRT-first platform that has expanded into adjacent categories (weight loss, sexual health, cognitive health) and is known for its comprehensive diagnostic baseline and physician-led protocol. Peter MD is a broader men's health platform that covers TRT, ED, hair loss, and weight management, with a more accessible entry price.

The key differentiator is clinical depth versus accessibility. Hone Health's diagnostic protocol is more rigorous — it requires a comprehensive hormone panel before prescribing and includes regular follow-up labs. Peter MD's entry price is lower and the onboarding is faster, but the clinical oversight is lighter. For men who want a thorough diagnostic baseline and a physician-led TRT protocol, Hone Health is the stronger choice. For men who want quick access at a lower price point, Peter MD is more accessible.

Hone Health logo

Hone Health

TRT & Men's Hormones · Editor 4.4

Hormone optimisation platform with real biomarker testing and physician-guided protocols, for men and women.

Pricing4.5
Experience4.6
Trust4.7
TRT at Hone
Peter MD logo

Peter MD

TRT & Men's Hormones · Editor 4.4

Affordable men's health clinic specialised in TRT and weight loss with transparent pricing.

Pricing4.5
Experience4.4
Trust4.4
Read full review
§ Side-by-Side

Side-by-Side Comparison

AttributeHone HealthPeter MD
Program FeeFrom $25/mo (membership)Included in monthly plan
Medication FromFrom $25 – $399/moFrom $79 – $349/mo
Editor Score4.4 / 54.4 / 5
Primary CategoryTRT & Men's HormonesTRT & Men's Hormones
FDA Brand-Name AccessCompounded onlyCompounded only
Compounded Options1 compounds2 compounds
Adjacent CategoriesTRT & Men's Hormones, Women's Health & HRTTRT & Men's Hormones, GLP-1 Weight Loss, Erectile Dysfunction, Hair Loss, Peptide Therapy, Primary Care
§ Clinical Evidence

What the Studies Actually Show

Testosterone reference ranges and clinical recommendations below are drawn from the 2018 Endocrine Society Clinical Practice Guideline (JCEM) and the AUA 2018 testosterone deficiency guideline. Both platforms operate within the standard of care; differences are in panel breadth, dosing forms, and add-on services rather than in the underlying medicine.

EndpointHone HealthPeter MD
Adult male total testosterone reference range (Endocrine Society)1264–916 ng/dL is the typical reference range; treatment is generally considered when total T is consistently below 264 ng/dL with symptomsSame
Recommended baseline biomarker panel1,2Total T, free T, SHBG, LH, FSH, estradiol, PSA (men over 40), CBC, CMP, lipids, hematocritTotal T, free T, estradiol, hematocrit, PSA, CMP
Hematocrit monitoring (key safety endpoint)2Required at baseline and at follow-up testing; treatment paused if HCT >54%Required at baseline and quarterly
Major TRT cardiovascular safety evidence3TRAVERSE trial (2023): TRT was non-inferior to placebo for major adverse cardiovascular events in middle-aged and older men with hypogonadism and elevated CV riskSame
Women's hormone supportYes, Hone+ for women includes thyroid, estrogen, progesterone, DHEA testingNo (men-only)
Bundled GLP-1 weight lossAvailable as add-onBundled into core subscription

Note on recommended baseline biomarker panelBoth panels meet the AUA minimum. Hone's panel is broader, which helps detect secondary causes of low T (e.g., elevated SHBG, hypogonadotropic hypogonadism).

Who Should Choose Hone Health vs Peter MD

Choose Hone Health if…

  • You want treatment decisions based on lab work, not a questionnaire.
  • You're a woman, or want one provider for a partner too: Hone treats both.
  • You're comfortable paying the $25 membership plus labs and medication.

Choose Peter MD if…

  • You're a man who wants TRT and weight-loss care in one transparent monthly price.
  • Price matters more than the depth of testing.

Monthly Cost Compared

Hone HealthPeter MD
Membership or program feeFrom $25/mo (membership)Included in monthly plan
Published priceFrom $25 – $399/moFrom $79 – $349/mo
All-in at a maintenance doseNot publishedNot published
Public reviews (Trustpilot)4.8/5 from 12,3113/5 from 11
Prices last checked15 June 202615 June 2026

Prices come from each provider's own pages on the dates shown and change often; maintenance figures include any required membership. Compare every provider in the GLP-1 price tracker.

The Verdict

Choose Hone Health for the data-driven protocol, broader biomarker panel, and the option to include women's hormone care. Choose Peter MD if you want a single male-focused subscription that handles both TRT and GLP-1 weight loss.

§ FAQ

Frequently Asked Questions

Is Hone Health or Peter MD cheaper for TRT?

Pricing is similar at the base subscription level (~$120–$180/mo all-in for injectable testosterone cypionate including consult and labs). Peter MD bundles GLP-1 weight-loss into the core subscription, which makes it cheaper for patients who want both TRT and weight loss; Hone charges separately for GLP-1 add-ons. For TRT alone, Hone tends to be modestly cheaper at standard dosing.

Which platform has the deeper biomarker panel?

Hone Health, by a wide margin. Hone's standard panel includes total T, free T, SHBG, LH, FSH, estradiol, PSA, CBC, CMP, lipids, and hematocrit. Peter MD's panel covers the AUA minimum (total T, free T, estradiol, hematocrit, PSA, CMP) but skips SHBG, LH, and FSH. The Hone panel is more useful for diagnosing secondary causes of low T and for distinguishing primary from secondary hypogonadism.

Does Peter MD prescribe enclomiphene?

As of 2026, Peter MD focuses primarily on injectable testosterone cypionate and does not feature enclomiphene as a first-line option. Hone Health offers enclomiphene as an alternative for younger patients and those who want to preserve fertility. Patients specifically seeking enclomiphene should consider MangoRx or Feel30 in addition to Hone.

Which platform handles women's hormones?

Hone Health. Peter MD is men-only. Hone+ for women includes thyroid, estrogen, progesterone, and DHEA testing alongside the male TRT program. Couples or households who want one platform for both partners can use Hone; Peter MD requires separate provider relationships for women.

How often are follow-up labs required?

Both platforms require follow-up labs at 8–12 weeks after starting TRT to confirm therapeutic levels and screen for hematocrit elevation. Hone defaults to quarterly labs in the first year then biannual; Peter MD operates similarly. Both pause therapy if hematocrit exceeds 54%, consistent with AUA and Endocrine Society guidance.

Which platform should I choose if I have GLP-1 and TRT goals?

Peter MD, the bundled subscription is meaningfully cheaper than buying TRT and GLP-1 separately. Peter MD's core subscription includes both, which removes the friction of managing two separate prescriptions and follow-up schedules. For TRT-only patients, Hone's broader biomarker panel and women's hormone option make it the stronger clinical fit.

References — Clinical Studies
  1. Endocrine Society Clinical Practice Guideline (Testosterone Therapy in Men with Hypogonadism, 2018) · Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018;103(5):1715–1744.
  2. TRAVERSE Trial. NEJM 2023 · Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med 2023;389:107–117.

RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.

§ Continue Reading